184 related articles for article (PubMed ID: 21479962)
1. The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma.
Hua W; Yao Y; Chu Y; Zhong P; Sheng X; Xiao B; Wu J; Yang B; Mao Y; Zhou L
J Neurooncol; 2011 Nov; 105(2):149-57. PubMed ID: 21479962
[TBL] [Abstract][Full Text] [Related]
2. Targeting cancer stem cells through L1CAM suppresses glioma growth.
Bao S; Wu Q; Li Z; Sathornsumetee S; Wang H; McLendon RE; Hjelmeland AB; Rich JN
Cancer Res; 2008 Aug; 68(15):6043-8. PubMed ID: 18676824
[TBL] [Abstract][Full Text] [Related]
3. Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.
Brown CE; Starr R; Martinez C; Aguilar B; D'Apuzzo M; Todorov I; Shih CC; Badie B; Hudecek M; Riddell SR; Jensen MC
Cancer Res; 2009 Dec; 69(23):8886-93. PubMed ID: 19903840
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells.
Sun JC; Pan K; Chen MS; Wang QJ; Wang H; Ma HQ; Li YQ; Liang XT; Li JJ; Zhao JJ; Chen YB; Pang XH; Liu WL; Cao Y; Guan XY; Lian QZ; Xia JC
Cancer Biol Ther; 2010 Aug; 10(4):368-75. PubMed ID: 20581468
[TBL] [Abstract][Full Text] [Related]
5. Anti-glioma response of autologous T cells stimulated by autologous dendritic cells electrofused with CD133+ or CD133- glioma cells.
Qin K; Tian G; Li P; Chen Q; Zhang R; Ke YQ; Xiao ZC; Jiang XD
J Neuroimmunol; 2012 Jan; 242(1-2):9-15. PubMed ID: 22123613
[TBL] [Abstract][Full Text] [Related]
6. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas.
Bexell D; Gunnarsson S; Siesjö P; Bengzon J; Darabi A
Int J Cancer; 2009 Jul; 125(1):15-22. PubMed ID: 19291792
[TBL] [Abstract][Full Text] [Related]
7. Limits of CD133 as a marker of glioma self-renewing cells.
Clément V; Dutoit V; Marino D; Dietrich PY; Radovanovic I
Int J Cancer; 2009 Jul; 125(1):244-8. PubMed ID: 19350631
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.
Ji J; Judkowski VA; Liu G; Wang H; Bunying A; Li Z; Xu M; Bender J; Pinilla C; Yu JS
Stem Cells Transl Med; 2014 Mar; 3(3):356-64. PubMed ID: 24375541
[TBL] [Abstract][Full Text] [Related]
9. CXCR4-positive subset of glioma is enriched for cancer stem cells.
Zheng X; Xie Q; Li S; Zhang W
Oncol Res; 2011; 19(12):555-61. PubMed ID: 22812188
[TBL] [Abstract][Full Text] [Related]
10. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.
Jamal M; Rath BH; Tsang PS; Camphausen K; Tofilon PJ
Neoplasia; 2012 Feb; 14(2):150-8. PubMed ID: 22431923
[TBL] [Abstract][Full Text] [Related]
11. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas.
Ogden AT; Waziri AE; Lochhead RA; Fusco D; Lopez K; Ellis JA; Kang J; Assanah M; McKhann GM; Sisti MB; McCormick PC; Canoll P; Bruce JN
Neurosurgery; 2008 Feb; 62(2):505-14; discussion 514-5. PubMed ID: 18382330
[TBL] [Abstract][Full Text] [Related]
12. Study on the proliferation and drug-resistance of human brain tumor stem-like cells.
Qin K; Jiang X; Zou Y; Wang J; Qin L; Zeng Y
Cell Mol Neurobiol; 2010 Aug; 30(6):955-60. PubMed ID: 20526804
[TBL] [Abstract][Full Text] [Related]
13. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells.
Barrantes-Freer A; Renovanz M; Eich M; Braukmann A; Sprang B; Spirin P; Pardo LA; Giese A; Kim EL
PLoS One; 2015; 10(6):e0130519. PubMed ID: 26086074
[TBL] [Abstract][Full Text] [Related]
14. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.
McCord AM; Jamal M; Shankavaram UT; Lang FF; Camphausen K; Tofilon PJ
Mol Cancer Res; 2009 Apr; 7(4):489-97. PubMed ID: 19372578
[TBL] [Abstract][Full Text] [Related]
15. B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells.
Yao Y; Wang X; Jin K; Zhu J; Wang Y; Xiong S; Mao Y; Zhou L
J Neurooncol; 2008 Sep; 89(2):121-9. PubMed ID: 18478183
[TBL] [Abstract][Full Text] [Related]
16. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells.
Yao Y; Tao R; Wang X; Wang Y; Mao Y; Zhou LF
Neuro Oncol; 2009 Dec; 11(6):757-66. PubMed ID: 19264916
[TBL] [Abstract][Full Text] [Related]
17. [Chemoresistance of CD133(+) tumor stem cells from human brain glioma].
Bi CL; Fang JS; Chen FH; Wang YJ; Wu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 32(4):568-73. PubMed ID: 17767043
[TBL] [Abstract][Full Text] [Related]
18. Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy.
Wu A; Wiesner S; Xiao J; Ericson K; Chen W; Hall WA; Low WC; Ohlfest JR
J Neurooncol; 2007 Jun; 83(2):121-31. PubMed ID: 17077937
[TBL] [Abstract][Full Text] [Related]
19. IL-10 and TGF-β2 are overexpressed in tumor spheres cultured from human gliomas.
Qiu B; Zhang D; Wang C; Tao J; Tie X; Qiao Y; Xu K; Wang Y; Wu A
Mol Biol Rep; 2011 Jun; 38(5):3585-91. PubMed ID: 21088899
[TBL] [Abstract][Full Text] [Related]
20. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells.
Lehnus KS; Donovan LK; Huang X; Zhao N; Warr TJ; Pilkington GJ; An Q
Int J Oncol; 2013 Mar; 42(3):1011-7. PubMed ID: 23340741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
